Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1a,Condition 1b,Condition 2,Condition 3 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,119.08,uV,22.02,53.9378,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + MPEP,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108524,DL-α-aminoadipate (70 ug/ul) ,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,584.5,uV,55.51,135.9712,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + MPEP,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108525,DL-α-aminoadipate (70 ug/ul) ,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,644.33,uV,50.52,123.7482,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + MPEP,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108526,DL-α-aminoadipate (70 ug/ul) ,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,739.67,uV,44.42,108.8063,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + MPEP,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108527,DL-α-aminoadipate (70 ug/ul) ,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,748.17,uV,64.77,158.6535,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + MPEP,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108528,DL-α-aminoadipate (70 ug/ul) ,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,800,uV,67.71,165.855,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + MPEP,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108529,DL-α-aminoadipate (70 ug/ul) ,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,a wave amplitude ERG,,7.44,uV,1.43,3.7834,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,4,days,2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108542,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,a wave amplitude ERG,,83.4,uV,14.8,39.1571,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,4,days,2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108543,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,a wave amplitude ERG,,145.24,uV,12.56,33.2306,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,4,days,2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108544,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,a wave amplitude ERG,,192,uV,14.42,38.1517,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,4,days,2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108545,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,a wave amplitude ERG,,233.29,uV,18.61,49.2374,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,4,days,2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108546,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,a wave amplitude ERG,,251.29,uV,19.14,50.6397,MMO:0000616,electroretinography,cornea,0.0,pbs,subretinal injection,4,days,2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108547,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,16.12,uV,3.84,9.406,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + MPEP,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108512,DL-α-aminoadipate (70 ug/ul) ,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,19.36,uV,3.48,8.5242,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + MPEP,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108513,DL-α-aminoadipate (70 ug/ul) ,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,112.85,uV,11.14,27.2873,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + MPEP,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108514,DL-α-aminoadipate (70 ug/ul) ,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,172.6,uV,20.12,49.2837,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + MPEP,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108515,DL-α-aminoadipate (70 ug/ul) ,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,208.5,uV,14.36,35.1747,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + MPEP,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108516,DL-α-aminoadipate (70 ug/ul) ,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,241.17,uV,16.89,41.3719,MMO:0000616,electroretinography,cornea,0.0,dl-aaa + MPEP,subretinal injection,2,days,DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108517,DL-α-aminoadipate (70 ug/ul) ,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,5.86,uV,0.7586,2.007,MMO:0000616,electroretinography,cornea,0.0,MPEP,subretinal injection,4,days,2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108536,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,11.45,uV,3.5617,9.4234,MMO:0000616,electroretinography,cornea,0.0,MPEP,subretinal injection,4,days,2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108537,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,18.52714286,uV,4.772,12.6256,MMO:0000616,electroretinography,cornea,0.0,MPEP,subretinal injection,4,days,2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108538,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,27.21857143,uV,4.739,12.5383,MMO:0000616,electroretinography,cornea,0.0,MPEP,subretinal injection,4,days,2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108539,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,33.73,uV,9.28,24.5526,MMO:0000616,electroretinography,cornea,0.0,MPEP,subretinal injection,4,days,2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108540,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,both,39 days,7,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,36.49,uV,10.37,27.4364,MMO:0000616,electroretinography,cornea,0.0,MPEP,subretinal injection,4,days,2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108541,2-methyl-6-(phenylethynyl)pyridine (200 umol) ,,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2))